Unprecedented Therapeutic Potential with a Combination of A2A/NR2B Receptor Antagonists as Observed in the 6-OHDA Lesioned Rat Model of Parkinson's Disease

Open Access

Peer-reviewed

Research Article

Unprecedented Therapeutic Potential with a Combination of A_2A/NR2B Receptor Antagonists as Observed in the 6-OHDA Lesioned Rat Model of Parkinson's Disease

Anne Michel ,

* E-mail: anne.michel@ucb.com

Affiliation Neurosciences TA Biology, UCB BioPharma SPRL, Braine l'Alleud, Belgium
⨯
Patrick Downey,

Affiliation Neurosciences TA Biology, UCB BioPharma SPRL, Braine l'Alleud, Belgium
⨯
Jean-Marie Nicolas,

Affiliation Non-Clinical Development, UCB BioPharma SPRL, Braine l'Alleud, Belgium
⨯
Dieter Scheller

Affiliation Neurosciences TA Biology, UCB BioPharma SPRL, Braine l'Alleud, Belgium
⨯

Receptor antagonist therapy
Is the Subject Area "Receptor antagonist therapy" applicable to this article?

Thanks for your feedback.
Levodopa
Is the Subject Area "Levodopa" applicable to this article?

Thanks for your feedback.
Drug administration
Is the Subject Area "Drug administration" applicable to this article?

Thanks for your feedback.
Drug interactions
Is the Subject Area "Drug interactions" applicable to this article?

Thanks for your feedback.
Parkinson disease
Is the Subject Area "Parkinson disease" applicable to this article?

Thanks for your feedback.
Dopaminergics
Is the Subject Area "Dopaminergics" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.
Rats
Is the Subject Area "Rats" applicable to this article?

Thanks for your feedback.